Company / Depreciation & Amortization
ENANTA PHARMACEUTICALS INC Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$2.4M
FY2025
5-year range
$2.4M / $3.6M
FY2021-FY2025
Trend
-20.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has declined for 3 consecutive years, from $4M in FY2022 to $2M in FY2025.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -1.2%.
Improved from $3M to $2M over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -13.3%
- 5-Year CAGR
- -1.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's depreciation & amortization has declined for 3 consecutive years.
- 5-year CAGR of -1.2%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 20.2% year-over-year.
- Peak depreciation & amortization was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.4M | -20.2% |
| FY2024 | $3.0M | -10.8% |
| FY2023 | $3.3M | -8.5% |
| FY2022 | $3.6M | +11.8% |
| FY2021 | $3.3M | +29.4% |
| FY2020 | $2.5M | +17.8% |
| FY2019 | $2.1M | +28.7% |
| FY2018 | $1.7M | +159.9% |
| FY2017 | $639.0K | +81.5% |
| FY2016 | $352.0K | +59.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026